The FDA has delayed new rule for off-label uses of pharmaceuticals.
After interferences from Pharma, the Food and Drug Administration (FDA) has delayed implementing a new rule that regulates off-label marketing.
The new rule regulates the way in which pharmaceutical manufacturers can discuss the unapproved uses of their products with health-care providers.
was delayed in an effort to recieve public comments. Device and pharma industry groups have accused the agency of ignoring proper rulemaking procedures.
The new rule would mean that drug makers must update a product label if there’s an indication that a company intends to use its medicine for an off-label or unapproved use.
Doctors sometimes prescribe drugs as a treatment for conditions outside of medications original purpose.
Companies can face criminal charges and liability if they tout their products to doctors and the public for off-label uses the FDA hasn’t specifically approved.
The FDA is pushing back the rule’s effective date to March 19, 2018. Nearly one year after it’s original date.